登录 注册 会员服务 联系我们

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

  • Published:2023-04-12 Issue:3 Volume:41 Page:391-401
  • ISSN:0167-6997
  • Container-title:Investigational New Drugs
  • language:en
  • Short-container-title:Invest New Drugs

Author:

Abuhadra Nour,Sun Ryan,Bassett Roland L.,Huo Lei,Chang Jeffrey T.,Teshome Mediget,Clayborn Alyson R.,White Jason B.,Ravenberg Elizabeth E.,Adrada Beatriz E.,Candelaria Rosalind P.,Yang Wei,Ding Qingqing,Symmans W. Fraser,Arun Banu,Damodaran Senthil,Koenig Kimberly B.,Layman Rachel M.,Lim Bora,Litton Jennifer K.,Thompson Alastair,Ueno Naoto T.,Piwnica-Worms Helen,Hortobagyi Gabriel N.,Valero Vicente,Tripathy Debu,Rauch Gaiane M.,Moulder Stacy,Yam Clinton

Funder

The Susan Papizan Dolan Fellowship in Breast Oncology

National Institutes of Health

Moon Shots Program of The University of Texas MD Anderson Cancer Center

Cancer Prevention and Research Institute of Texas

Still Water Foundation

Novartis Pharmaceuticals Corporation

Pfizer

The Winterhof Fund

Conquer Cancer Foundation

The Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Reference38 articles.

1. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

2. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A (2020) Pathologic complete response after neoadjuvant chemotherapy and impact on breast Cancer recurrence and survival: a Comprehensive Meta-analysis. Clin Cancer Res 26(12):2838–2848. https://doi.org/10.1158/1078-0432.CCR-19-3492

3. Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA (2020) Association of Pathologic Complete response with long-term survival outcomes in Triple-Negative breast Cancer: a Meta-analysis. Cancer Res 80(24):5427–5434. https://doi.org/10.1158/0008-5472.CAN-20-1792

4. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after Neoadjuvant Chemotherapy Associated with residual Cancer burden and breast Cancer subtype. J Clin Oncol 35(10):1049–1060. https://doi.org/10.1200/JCO.2015.63.1010

5. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422. https://doi.org/10.1200/JCO.2007.10.6823
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3